Marvel Biosciences Corp Total Liabilities
Marvel Biosciences Corp total liabilities. Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has total liabilities worth CA$4.33 Million CAD (≈ $3.14 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Marvel Biosciences Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Marvel Biosciences Corp (2020–2025)
Total liabilities of Marvel Biosciences Corp from 2020 to 2025. This chart illustrates how Marvel Biosciences Corp's total liabilities have evolved over time, based on quarterly financial data.
Marvel Biosciences Corp Competitors by Total Liabilities
The table below lists competitors of Marvel Biosciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Throgmorton Trust Plc
LSE:THRG
|
UK | GBX6.49 Million |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
USA | $9.13 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
UK | GBX3.69 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
UK | GBX93.06 Million |
|
Quantum Genomics SA
PA:ALQGC
|
France | €2.81 Million |
|
SIV Capital Ltd
AU:SIV
|
Australia | AU$113.58K |
Liability Composition Analysis (2020–2025)
This chart breaks down Marvel Biosciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Marvel Biosciences Corp balance sheet assets.
Liquidity & Leverage Metrics
Marvel Biosciences Corp Total Liabilities Ratios Explained
Marvel Biosciences Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marvel Biosciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marvel Biosciences Corp (2020–2025)
The table below shows the annual total liabilities of Marvel Biosciences Corp from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$4.33 Million ≈ $3.13 Million |
+30.62% |
| 2024-07-31 | CA$3.32 Million ≈ $2.40 Million |
+38.65% |
| 2023-07-31 | CA$2.39 Million ≈ $1.73 Million |
+233.21% |
| 2022-07-31 | CA$718.00K ≈ $519.39K |
+538.36% |
| 2021-07-31 | CA$112.48K ≈ $81.36K |
-36.52% |
| 2020-07-31 | CA$177.18K ≈ $128.17K |
-- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more